Jul 19, 2022 PharmaCyte Biotech Reports Positive Interim Results in Malignant Ascites Mouse Model Study
Jul 11, 2022 PharmaCyte Biotech Announces Preliminary Unaudited Financial Results for Fiscal Year 2022
Jul 5, 2022 PharmaCyte Biotech Announces Additional Quality Control Assay and Confirms Stability of CypCap Cells
Jun 15, 2022 PharmaCyte Biotech Issues Follow-Up Response to Iroquois Capital’s Second Letter on June 9 and Reiterates Commitment to Increasing Shareholder Value
Jun 8, 2022 PharmaCyte Biotech Issues Response to Iroquois Capital Letter and Announces Additional Steps to Increase Shareholder Value
May 23, 2022 PharmaCyte Biotech Initiates Studies to Confirm Its Pancreatic Cancer Therapy Can Treat Malignant Ascites
Apr 27, 2022 PharmaCyte Biotech to Attend 15th International Conference on Advanced Technologies and Treatments for Diabetes
Apr 19, 2022 PharmaCyte Biotech Announces More Positive Tests Results for Its Pancreatic Cancer Clinical Trial Product Candidate to Satisfy FDA Requirements
